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Abstract Of the two rhesus macaque subspecies used for
AIDS studies, the Simian immunodeficiency virus-infected
Indian rhesus macaque (Macaca mulatta) is the most
established model of HIV infection, providing both insight
into pathogenesis and a system for testing novel vaccines.
Despite the Chinese rhesus macaque potentially being a
more relevant model for AIDS outcomes than the Indian
rhesus macaque, the Chinese-origin rhesus macaques have
not been well-characterized for their major histocompati-
bility complex (MHC) composition and function, reducing
their greater utilization. In this study, we characterized a
total of 50 unique Chinese rhesus macaques from several
varying origins for their entire MHC class I allele
composition and identified a total of 58 unique complete
MHC class I sequences. Only nine of the sequences had
been associated with Indian rhesus macaques, and 28/58
(48.3%) of the sequences identified were novel. From
all MHC alleles detected, we prioritized Mamu-
A1*02201 for functional characterization based on its
higher frequency of expression. Upon the development of
MHC/peptide binding assays and definition of its associ-
ated motif, we revealed that this allele shares peptide
binding characteristics with the HLA-B7 supertype, the
most frequent supertype in human populations. These
studies provide the first functional characterization of an
MHC class I molecule in the context of Chinese rhesus
macaques and the first instance of HLA-B7 analogy for
rhesus macaques.
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Introduction
Rhesus macaques have been extensively used in infectious
disease research for several indications, most notably HIV/
AIDS. Macaque models have provided key insights into
disease pathogenesis and allow for the evaluation of novel
vaccine concepts. Two subspecies of rhesus macaques,
consisting of Indian-origin rhesus macaques and Chinese-
origin rhesus macaques, have been utilized extensively in
AIDS research and for other models of infectious disease
(Desrosiers 1990; Gardner and Luciw 2008; Haigwood
2009; ILAR 2003; Kindt et al. 1992; Persidsky and Fox
2007). While physiologically these two subspecies appear
to be nearly identical, genetic factors that can affect
immune responses are quite varied, which may underlie
the disparate outcomes of infections seen in these two
subspecies (Joag et al. 1994; Ling et al. 2002; Otting et al.
2007, 2005). In the context of Simian immunodeficiency
virus (SIV) research, the vast majority of studies performed
with Indian rhesus macaques have shown progression to
AIDS in a shorter time period compared with HIV-infected
humans (Miller et al. 1989; Smith et al. 1999). For this
reason, researchers have investigated other nonhuman
primate animal models to more closely mimic HIV
infections in humans. Chinese rhesus macaques have been
an interesting choice because SIV infection in these animals
yields a prolonged disease progression, more similar to HIV
infection in humans (Joag et al. 1994; Ling et al. 2002;
Reimann et al. 2005).
Several independent observations have implicated cellu-
lar immunity, specifically cytotoxic T lymphocyte (CTL)
responses, in the control of AIDS viral replication (Brander
et al. 2001; Kalams et al. 1999; Kuroda et al. 1999; Schmitz
et al. 1999). Major histocompatibility complex (MHC) class
I and II molecules determine the repertoire of T cell
responses that an individual can develop against SIV and/
or any other foreign pathogen (Parham 2005). The Indian
rhesus macaques have been extensively characterized in
terms of their MHC allele composition, resulting in
instrumental findings in the setting of SIV infection,
including the discovery of viral evasion from CTL
responses (Allen et al. 2000; Evans et al. 1999)a n d
identification of specific MHC alleles which influence
disease progression (Loffredo et al. 2007; Mothe et al.
2003; O'Connor et al. 2003; Pal et al. 2002; Yant et al.
2006). Several macaque MHC (Mamu) class I alleles,
including Mamu-A*01 (Allen et al. 1998), B*17 (Mothe et
al. 2002), and B*01 (Loffredo et al. 2005) among others
(Loffredo et al. 2004; Sette et al. 2005) are expressed with
high frequency (over 10%) in specific macaque popula-
tions. The fact that Indian rhesus macaques used in
biomedical research in the USA have been interbreeding
since 1978, when India banned the exportation of these
animals (Southwick and Siddiqi 1988), is probably a major
contributing factor to the high frequency of expression of
these MHC class I molecules. Because of the extensive
characterization of their MHC alleles, Indian rhesus
macaques are the most widely utilized animal model in
AIDS research studies (Gardner and Luciw 2008; Patterson
and Carrion 2005; Persidsky and Fox 2007; Watkins et al.
2008). However, as previously mentioned, the rapid
progression to disease displayed after SIV infection of
Indian rhesus macaques and, more recently, the increased
demand for these animals has led to the desire in
developing alternative animal models.
Chinese rhesus macaques are relatively accessible for
research, but are not as well-characterized at their MHC
loci. Although studies have been performed in recent years
to address this shortcoming (Karl et al. 2008; Ma et al.
2009; Otting et al. 2007, 2005, 2008; Ouyang et al. 2008;
Wiseman et al. 2009), these studies have not yet generated
any functional data in terms of epitopes recognized or the
specific biological relevance of these MHC molecules upon
infection. This lack of information makes it difficult to
interpret data with respect to immune correlates of
protection, especially in terms of CTL immune responses
and thereby severely hinders the greater use of Chinese
macaques as animal models for infectious disease research.
Thus, while researchers have shown that Chinese rhesus
macaques are of value as animal models for AIDS vaccine
development and for other pathogens, their full potential
has not been realized due to missing functional MHC and
genetic information. In this study, we sought to characterize
50 unique Chinese rhesus macaque samples in detail for
their entire MHC class I allele composition. Since these
animals were derived from several national primate centers
and sources, this provided a glimpse into the MHC
composition of animals that reflect their vast geographic
diversity. Furthermore, we thoroughly characterized the
MHC/peptide binding motif of the most common MHC
class I molecule in Chinese rhesus macaques, yielding the
first functional MHC data in this subspecies.
Materials and methods
Sample acquisition, RNA isolation, and cDNA synthesis
We obtained peripheral blood mononuclear cells (PBMCs)
from 12 animals from the Tulane National Primate Center
(New Orleans, LA, USA), and from the Scripps Research
Institute (La Jolla, CA, USA) for 11 others. Blood from 27
animals at the Washington National Primate Research
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Blood RNA tubes (Qiagen, Valencia, CA, USA).
We isolated RNA and DNA from PBMC samples using
the Qiagen QIAshredder tissue homogenizer and the
Qiagen AllPrep DNA/RNA Mini kit following the manu-
facturer's protocols. We used the PAXgene Blood RNA kit
(Qiagen) to isolate RNA from the PAXgene Blood RNA
tubes. Complementary DNA (cDNA) was synthesized
using the Superscript III First-Strand Synthesis kit for RT-
PCR (Invitrogen, Carlsbad, CA, USA) for all the samples.
PCR amplification, cloning, and sequencing of MHC class
I transcripts
We performed polymerase chain reaction (PCR) for the
MHC class I transcripts and cloned them as previously
described (Karl et al. 2008). DNA from each clone was
subjected to bidirectional sequencing using previously
published primer sequences (Wiseman et al. 2007). Gene-
wiz, Inc. (San Diego, CA, USA) sequenced the samples
using the Sanger dideoxy method on an Applied Biosys-
tems Prism 3730xl DNA analyzer (Foster City, CA, USA).
We utilized the CodonCode Aligner (CodonCode, Dedham,
MA, USA) software package to analyze the sequence data.
To identify the most highly expressed transcripts, we
sequenced 88 clones from each animal. We required a
sequence to be found in at least three clones from a unique
animal/locus pair to avoid analysis of aberrant mutations
introduced in the PCR. Novel sequences were submitted to
GenBank. Additionally, sequence information was submit-
ted to the IMGT/MHC Nonhuman Primate Immuno
Polymorphism (IPD-MHC) Nomenclature Committee for
naming of the novel alleles (Robinson et al. 2003).
Creation of stable MHC class I transfectants
Stable MHC class I transfectants were produced in the
MHC class I-deficient EBV-transformed B-lymphoblastoid
cell line 721.221. For each of the alleles studied (Mamu-
A1*02201 and Mamu-B*08301), we created an expression
construct by subcloning a full-length allele transcript into
the pcDNA 3.1 vector (Invitrogen). This construct was then
used to transfect 721.221 cells using an Amaxa Nucleo-
fector II transfection machine (Lonza AG, Walkersville,
MD, USA).
Positional scanning combinatorial library and peptide
synthesis
Positional scanning combinatorial libraries (PSCL) were
synthesized as previously described (Pinilla et al. 1999).
PCSL are composed of systematically arranged mixtures,
and each mixture in the library contains 9-mer peptides
with one fixed residue at a single position. With each of the
20 naturally occurring residues represented at each position
along a 9-mer backbone, the entire library consisted of 180
peptide mixtures.
Peptides utilized in screening studies were purchased as
crude or purified material from Mimotopes (Minneapolis, MN,
USA/Clayton, Victoria, Australia), Pepscan Systems B. V.
(Lelystad,Netherlands),AandALabs(SanDiego,CA,USA),
Genescript Corporation (Piscataway, NJ, USA), or the
Biotechnology Center at the University of Wisconsin-
Madison (Madison, WI, USA). Peptides synthesized for use
as radiolabeled ligandsweresynthesized by A and A Labsand
purifiedto>95% homogeneitybyreverse-phaseHPLC.Purity
of these peptides was determined using analytical reverse-
phase high performance liquid chromatography (HPLC) and
amino acid analysis, sequencing, and/or mass spectrometry.
Peptides were radiolabeled utilizing the chloramine T method
(Sidney et al. 2001). Lyophilized peptides were resuspended
at 4–20 mg/ml in 100% DMSO, then diluted to required
concentrations in PBS +0.05% (v/v) Nonidet P40 (Fluka
Biochemika, Buchs, Switzerland).
SIV peptide sequences were derived from the SIV-
mac239 sequence, GenBank accession M33262 (Kestler et
al. 1990).
MHC purification and peptide binding assays
HLA and Mamu class I MHC purification was performed
by affinity chromatography using the W6/32 and/or B123.2
class I antibodies, as previously described (Loffredo et al.
2009; Sidney et al. 2001, 2005). Protein purity, concentra-
tion, and depletion efficiency steps were monitored by
SDS-PAGE.
Quantitative assays for peptide binding to detergent
solubilized MHC class I molecules were based on the
inhibition of binding of a high affinity radiolabeled
standard probe peptide and performed as detailed in prior
studies (Loffredo et al. 2004; Schneidewind et al. 2008;
Sidney et al. 2001, 2005). Peptides were tested at six
different concentrations covering a 100,000-fold dose range
in three or more independent assays. Control wells to
measure non-specific (background) binding were also
included. In each experiment, a titration of the unlabeled
version of the radiolabeled probe was also tested as a
positive control for inhibition. The radiolabeled peptide
utilized for the Mamu-A1*02201, and HLA-B7 supertype
assays was 1021.05 (FPFKYAAAF, a B35 consensus
sequence), with the exception of HLA-B*0702 which used
1075.23, a human A2 signal sequence p5 analog peptide
(APRTLVYLL). For each peptide, the concentration of
peptide yielding 50% inhibition of the binding of the
radiolabeled probe peptide (IC50) was calculated. Under the
conditions used, where [radiolabeled probe] < [MHC] and
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approximations of the true Kd values (Cheng and Prusoff
1973; Gulukota et al. 1997; Sette et al. 1994a).
Bioinformatic analysis
We performed analysis of the PSCL data as described
previously (Sidney et al. 2008). Briefly, IC50 nM values for
each residue–position mixture were standardized as a ratio
to the geometric mean IC50 nM value of the entire set of
180 mixtures and further normalized to the average of
libraries tested at each position. To identify predicted
binders, all possible 9-mer peptides in SIVmac239 sequen-
ces were scored using the matrix values derived from the
PSCL analysis of Mamu-A1*02201. The final score for
each peptide represents the product of the corresponding
matrix values for each peptide residue–position pair.
Peptides scoring among the top 3.0% were selected for
binding analysis.
Phylogenetic analysis
We assembled representative MHC class I sequences from
humans (HLA), Chinese, and Indian rhesus macaques.
Sequences were normalized to 1,068 nucleotides in length
and aligned using the ClustalX program (Thompson et al.
2002). A phylogenetic tree was built using the neighbor-
joining method (Saitou and Nei 1987). One thousand
bootstrap samples were analyzed to ensure reliable
clustering.
Accession codes
MHC class I allele sequences were submitted to GenBank
(accession numbers GQ902065-GQ902079, GU057837,
GU057840–GU057846, GU080236–GU080246,
GU120061, GU190191–GU190209, and GU198751–
GU198752).
Results
Non-overlapping MHC class I repertoires in Indian
and Chinese rhesus macaques
To analyze the frequency and functional features associated
with the MHC class I alleles expressed by Chinese origin
macaques, we assembled a cohort of 50 different animals
derived from various colonies currently utilized in biomed-
ical research. Samples were obtained from the Scripps
Research Institute (n=11), the Tulane National Primate
Research Center (n=12), and the Washington National
Primate Research Center (n=27). cDNA clones were
sequenced from each of the individual macaques and
assembled according to the described methods to generate
a complete snapshot of the highly expressed MHC class I
transcripts within the population of 50 animals.
In our study, we detected 58 distinct MHC class I A and
B loci transcripts (Supplemental Table 1 online). Only nine
of these had been previously detected in Indian-origin
macaques (Mamu-A2*2402,M a m u - A4*1403,M a m u -
B*00301,M a m u - B*00401,M a m u - B*00703,M a m u -
B*03003,M a m u - B*03901,M a m u - B*04002,a n d
Mamu-B*06901; Karl et al. 2008; Otting et al. 2007,
2005, 2008), yielding 49 sequences that were only detected
in Chinese rhesus macaques. These results demonstrate that
the repertoire of allelic variants found in Indian- and
Chinese-origin macaques is largely non-overlapping. The
limited allele sharing between Indian- and Chinese-origin
animals was previously noted and suggests that some of the
allelic polymorphism seen in the Chinese population may
have arisen after geographic isolation of the two subspecies
(Otting et al. 2007).
High degree of polymorphism in Mamu-A and B alleles
in Chinese macaques
Of the 58 MHC class I A and B loci transcripts identified in
this study, 28 represent novel sequences (13 novel alleles
from the Mamu-A locus and 15 from the Mamu-B locus),
including 16 that were detected in more than one animal
(Table 1). Sixteen of the novel transcripts encode unique
protein products, while 12 of the novel sequences are full-
Table 1 Novel and extended Mamu MHC class I allele transcripts
detected in multiple animals
Allele Positive
animals
Frequency
(%)
Accession
Number
A1*0040202 7 14 GU080238
B*08203 5 10 GU080243
A1*07401 5 10 GQ902065
A2*2403 5 10 GQ902068
A1*08501 4 8 GQ902067
B*03701 4 8 GU080239
B*00704 4 8 GQ902078
B*900202 3 6 GU080246
B*04803 3 6 GU057846
B*09003 3 6 GU080245
B*05601 3 6 GQ902079
A1*01803 3 6 GQ902071
B*06905 2 4 GU057842
A1*0320102 2 4 GQ902072
B*06004 2 4 GU057844
B*11601 2 4 GU057845
454 Immunogenetics (2010) 62:451–464length transcripts of sequences that had been previously
published as partial coding sequences. Two of the novel
sequences, B*03701 and A1*0040202, are noteworthy
because they exhibit very distinct nucleotide and amino
acid differences from any full-length published allele, yet
are present with appreciable frequency within our popula-
tion (four and seven animals, representing 8% and 14%,
respectively). Interestingly, an allele previously identified in
Cynomolgus macaques was also identified in one animal
(Mamu-B*1470101, identical to Mafa-B*04701). Given
that there were 58 distinct transcripts detected in a cohort
of 50 animals, these results demonstrate that a high amount
of polymorphism exists within the MHC class I A and B
loci of Chinese-origin macaques. Furthermore, that 48.3%
(28/58) of the transcripts were novel underscores the need
for continued sequencing efforts in this population.
MHC class I frequencies detected in Chinese macaques
from multiple colonies
A total of 32 alleles detected in this study share translated
sequences with alleles that had been reported in previous
studies utilizing different animal cohorts (Karl et al. 2008;
Ma et al. 2009; Otting et al. 2007; Ouyang et al. 2008).
These alleles are of interest, since they are likely to
represent alleles truly more prevalent in the Chinese
macaque population and not alleles whose frequencies are
inflated by founder effects and inbreeding in specific
animal colonies. Although we have not performed pedigree
analysis on the animals to ascertain their relationships due
to their diverse origins and the lack of complete history on
their initial Chinese colony information, we feel that the
diversity of the sources reduces the chance that allele
frequencies might be artificially inflated due to familial
relatedness.
Accordingly, we list in Table 2 alleles detected in our
cohort, and also detected in the previously published
studies, together with their frequency within our cohort,
and frequencies calculated by compilation of previous
studies. Where possible, in compiling this data we grouped
previously published partial coding sequences with their
full-length cognate sequences from our study for purposes
of frequency analysis. This analysis reveals 11 alleles that
are found in multiple animals in both sets of studies,
exhibiting a combined frequency greater than or equal to
5.6% for each allele. These alleles are Mamu-A1*02201,
Mamu-A1*02601,M a m u - A7*0103,M a m u - B*08301,
Mamu-B*06601,M a m u - B*03901,M a m u - B*01001,
Mamu-B*00301,M a m u - B*08701,M a m u - B*00101,a n d
Mamu-A2*0102. Combined, these alleles provide coverage
for approximately 68% of all Chinese rhesus animals
studied thus far by us and others, assuming that none of
these alleles are co-inherited. In conclusion, these data
identify a set of Mamu MHC class I alleles that are most
frequent within Chinese-origin macaques derived from
disparate animal colonies and therefore represent a logical
target for further analysis and characterization.
Establishment of the Mamu-A1*02201 peptide binding
assay
Next, we decided to investigate the function of the most
frequent allele identified above, Mamu-A1*02201.M H C
class I molecules expressed in a single cell transfectant
were purified by affinity chromatography. A transfectant
expressing the common allele Mamu-B*08301, previously
generated in the context of an independent project, was also
included in these investigations as a control.
Endogenous ligands or defined epitopes for the Mamu-
A1*02201 or Mamu-B*08301 molecules have not been
reported. However, previous studies demonstrated that
HLA supertype ligands also bind to MHC molecules
expressed in other species, such as chimpanzees (Pan
troglodytes) or mice (Mus musculus; McKinney et al. 2000;
Sette et al. 2005; Sidney et al. 2006). Accordingly, we
investigated the ability of purified Mamu-A1*02201 or
Mamu-B*08301 to bind a panel of radiolabeled ligands
representative of the main human HLA supertypes (HLA-
A1, HLA-A2, HLA-A3, HLA-A24, HLA-B7, and HLA-
B44; Fig. 1a, c).
In the case of Mamu-A1*02201 (Fig. 1a), the B7
supertype ligand FPFKYAAAF was associated with prom-
inent binding, and no binding was detected with the other
supertype ligands. Significant binding was observed with as
little as 0.43 nM of purified MHC. Mamu-A1*02201 bound
the B7 supertype ligand selectively, since no significant
binding was observed for any of the other radiolabeled
ligands examined. Furthermore, the binding was specific, in
that it could be inhibited by excess unlabeled
FPFKYAAAF, with an IC50 of approximately 1.9 nM
(Fig. 1b).
Further evidence of the allelic specificity of the binding
activity was demonstrated by the experiments examining
purified Mamu-B*08301. This molecule did not bind the
FPFKYAAAF ligand, but did bind the A3 supertype ligand
3035.0857 (KSINKVYGR) (Fig. 1c). In conclusion, these
results demonstrate the development of a Mamu-A1*02201
binding assay, thus enabling detailed investigation of the
peptide binding specificity of this MHC molecule.
Definition of Mamu-A1*02201 peptide-binding motif
To determine the capacity of Mamu-A1*02201 to bind
peptide ligands of differing lengths, combinatorial peptide
libraries of 7, 8, 9, and 10 amino acids in length,
synthesized as described in the Materials and methods
Immunogenetics (2010) 62:451–464 455section, were tested as inhibitors in the Mamu-A1*02201
binding assay (data not shown). The 9-mer-size library
exhibited the best binding affinity, with an average IC50 of
14,700 nM. A 10-mer library bound with slightly lower
affinity (19,600 nM). The 8-mer and 11-mer libraries bound
with even lower affinities (IC50 greater than 41,000 nM).
These data suggest the optimal peptide length for binding to
Mamu-A1*02201 is nine amino acids.
We next tested the capacity of a 9-mer PSCL to bind
Mamu-A1*02201 molecules (Fig. 2). The binding capacity
relative to the geometric mean for the entire PSCL (IC50=
2681 nM) was determined for each mixture with a defined
amino acid and further normalized to the average of activity
of the mixtures tested at each position, as previously
described (Sidney et al. 2008). The resulting matrix was
used to derive a Mamu-A1*02201 motif (Fig. 3). For this
analysis, we defined preferred residues as those that
displayed 20-fold higher binding capacity than the position
average and defined tolerated residues as those that
displayed fourfold higher binding. We defined a main
binding anchor as a position in which at least half of the
residues (≥10) are associated with binding capacity either
fourfold higher (in blue in Fig. 2) or lower (in orange in
Fig. 2) than the position average. Furthermore, secondary
anchor positions are defined as those associated with at
least five residues (25%), but less than ten, meeting the
described binding criteria.
Accordingly, position 2 and the C terminus are the main
anchor positions. At position 2, proline (P) was over-
whelmingly preferred above all others, and V, A, and I were
Allele
a Present study Previous studies
b Overall
Positive animals Frequency (%) Positive animals Frequency (%) Frequency (%)
c
A1*02201 1 2.0 15 11.6 8.9
A1*02601 7 14.0 5 3.9 6.7
A7*0103 3 6.0 8 6.2 6.1
B*08301 4 8.0 3 4.3 5.8
B*06601 4 8.0 3 4.3 5.8
B*03901 4 8.0 3 4.3 5.8
B*01001 4 8.0 3 4.3 5.8
B*00301 4 8.0 3 4.3 5.8
B*08701 3 6.0 4 5.7 5.8
B*00101 2 4.0 5 7.1 5.8
A2*0102 7 14.0 3 2.3 5.6
B*00704 4 8.0 2 2.9 5.0
B*00401 4 8.0 2 2.9 5.0
A1*00704 3 6.0 6 4.7 5.0
B*00703 3 6.0 3 4.3 5.0
B*00702 3 6.0 3 4.3 5.0
A1*04301 5 10.0 3 2.3 4.5
B*05601 3 6.0 2 2.9 4.2
A2*2403 5 10.0 1 0.8 3.4
A1*03201 3 6.0 3 2.3 3.4
A1*05602 2 4.0 4 3.1 3.4
B*04002 3 6.0 1 1.4 3.3
A1*08501 4 8.0 1 0.8 2.8
B*06902 1 2.0 2 2.9 2.5
B*03003 1 2.0 2 2.9 2.5
A1*01803 3 6.0 1 0.8 2.2
A1*05701 1 2.0 3 2.3 2.2
A1*01804 2 4.0 1 0.8 1.7
A4*1403 1 2.0 2 1.6 1.7
A2*0514 1 2.0 2 1.6 1.7
A1*04901 1 2.0 2 1.6 1.7
B*03602 1 2.0 1 1.4 1.7
Table 2 Mamu MHC class I
alleles detected in the present
study and in previous studies
aAlleles with variant nucleotide
sequences that yield synonymous
protein translations and full-length
versions of reported partial coding
sequences are listed as one allele
for simplicity
bData from previously published
studies is compiled (Karl et al.
2008; Ma et al. 2009; Otting et al.
2007; Ouyang et al. 2008)
cThe top 11 alleles in combined
frequency (≥5.6%) are in bold
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Fig. 1 The development of the Mamu-A1*02201 MHC/peptide
binding assay. Radiolabeled ligand probes for six major HLA class I
supertypes were used in a Mamu-A1*02201 and c Mamu-B*08301
direct binding dose titration experiments to ascertain binding potential
to the purified MHC molecules. HLA supertype ligands are
denoted by: solid circle, YTAVVPLVY, human J chain p102 (HLA-
A1 supertype); open circle, YVIKVSARV, MAGE1 p282 (HLA-A2
supertype); solid square, KSINKVYGR, Vaccinia p63 (HLA-A3
supertype); open square, AYIDNYNKF, A24 consensus sequence
(HLA-A24 supertype); solid triangle, FPFKYAAAF, B35 consensus
sequence (HLA-B7 supertype); and open triangle, SEIDLILGY,
naturally processed (HLA-B44 supertype). In the case of Mamu-
A1*02201, the HLA-B7 supertype ligand was associated with
prominent binding, whereas Mamu-B*08301 displayed significant
binding only to the HLA-A3 supertype ligand. b Inhibition of HLA-
B7 ligand binding to Mamu-A1*02201 by unlabeled ligand in dose
titration binding experiments (1.9 nM) demonstrated specificity of
ligand binding
Residue 123456789
A 4.7 7.0 3.0 1.5 1.0 1.2 1.2 7.6 4.3
C 1.6 0.28 0.19 1.1 0.69 0.52 0.76 0.73 0.78
D 0.082 0.16 2.3 0.87 0.83 0.25 1.4 1.1 0.18
E 0.037 0.16 0.060 0.048 0.41 0.25 1.3 0.15 0.27
F 1.4 0.23 9.3 4.2 2.0 1.3 2.3 1.7 63
G 0.57 0.20 2.0 1.4 1.8 1.9 1.2 1.1 1.1
H 1.2 0.30 1.1 1.3 0.93 1.6 0.80 0.17 1.0
I 1.3 6.1 4.2 0.76 1.7 1.2 2.7 1.3 0.59
K 0.44 0.21 0.15 0.76 0.21 0.56 0.19 0.16 0.18
L 1.3 3.1 0.43 0.98 0.84 11 1.7 1.1 4.6
M 1.4 1.0 2.6 3.0 0.53 1.3 1.1 1.4 14
N 0.39 0.85 1.9 1.3 1.1 0.60 0.92 0.62 0.46
P 0.15 230 0.25 1.0 1.7 1.1 1.1 2.7 0.18
Q 0.35 1.7 1.5 1.8 1.1 0.99 1.3 0.88 0.18
R 56 0.42 0.15 1.8 0.35 0.40 0.17 1.1 0.18
S 6.5 3.0 3.6 1.3 2.6 2.1 1.1 3.1 0.24
T 1.3 1.2 1.9 0.56 1.4 1.2 0.86 2.4 0.26
V 1.2 9.3 1.1 0.91 1.0 1.7 1.2 4.1 1.0
W 2.8 0.37 0.79 0.64 2.8 0.57 0.95 0.30 1.5
Y 1.5 0.23 1.5 0.67 1.1 1.1 1.2 0.81 47
Position Fig. 2 The relative influence of
amino acids at each position on
the binding to Mamu-
A1*02201. The 9-mer positional
scanning combinatorial library
was tested for binding to Mamu-
A1*02201. Values represent the
ratio of the IC50 nM of each
pool at a given position relative
to the geometric mean for the
entire library (2681 nM) and
further normalized to the aver-
age of libraries tested at each
position. Ratios of 0.25 or less
are highlighted in orange;> 4
are in blue
Immunogenetics (2010) 62:451–464 457somewhat tolerated. At the C terminus, the aromatic
residues F and Y were preferred, and M, L, and A were
tolerated. Using the criteria described above, position 1 was
identified as a secondary anchor with a strong preference
for R, while S and A residues were tolerated. Additionally,
at position 1, the residues D and E, and to a lesser extent P,
were associated with substantial decreases in binding
capacity. Significant, but less pronounced, effects were also
seen in positions 3 and 8, suggesting that these positions are
also secondary anchors. The influence of specific residues
at most other non-anchor positions was minimal, but in
general, aromatic, and aliphatic residues were associated
with contributing positive binding energy, whereas charged
residues, both acidic and basic, were associated with
deleterious effects.
Identification of Mamu-A1*02201 peptide ligands
Next, we tested the usefulness of the PSCL-based motif as a
means to identify Mamu- A1*02201 binding peptides. We
targeted the SIV proteome for these experiments, as
Chinese rhesus macaques are an increasingly utilized
animal model in SIV pathogenesis studies (Burdo et al.
2005; Degenhardt et al. 2009; Joag et al. 1994; Ling et al.
2002; Monceaux et al. 2007; Reimann et al. 2005; Trichel
et al. 2002). The PSCL matrix was used to score 9-mer
peptides in the SIVmac239 proteome. Eighty-one peptides
scoring in the upper 3.0% range were tested for binding
capacity (Supplemental Table 2 online). A set of 40 lower-
scoring control peptides, ranging from 5–50% in rank, was
also tested.
As previously described, 500 nM has been established as
an appropriate threshold for sufficient peptide binding in
SIV epitope and in vivo T cell recognition studies (Allen et
al. 2001; Loffredo et al. 2005, 2004; Mothe et al. 2002;
Sette et al. 2005, 1994a, 1994b; van der Most et al. 1998;
Vitiello et al. 1996). In our experiments, we used the
500 nM threshold to classify peptides as positive binders. In
total, 13 of the 81 “top 3% score” peptides bound Mamu-
A1*02201 with an affinity of 500 nM or less (Table 3). By
contrast, none of the 40 lower-scoring control peptides
resulted in similar affinities.
Mamu-A1*02201 and the HLA-B7 supertype MHC mole-
cules share overlapping binding repertoires
The results above define a Mamu-A1*02201 motif that
closely matches the motif associated with HLA-B7 super-
Residues with 4-fold 
ratio increase
R 
SA
P
VAI
FI F L AV FY
MLA
1 2 345678 9
Residues with 4-fold 
ratio decrease DEP DEFGKY EKRC E K D RK EHK DKRPQS
Number of residues 
affecting binding per 
position
6 1 0 621225 1 1
1
o anchor 1
o anchor
Position
Fig. 3 Map of the Mamu-A1*02201 motif. Pictorial summary
representation of the Mamu-A1*02201 PSCL matrix, indicating
residues contributing positive or negative binding potential by
position. The total number of residues affecting binding by position
is summed, with a double-digit score indicating primary anchor
position. Preferred residues at anchor positions, defined as residues
showing a 20-fold increase in binding capacity versus the position
average, are highlighted in larger font. Positions 2 and the C terminus
are identified as main anchor positions
Table 3 The efficiency of PSCL matrices in predicting Mamu-
A1*02201 binders
Peptides tested
a Mamu-A1*02201 binding affinity
(IC50nM)
Prediction rank n <50 50–500 >500
Top 0.75% 18 4 5 9
0.76–1.5% 22 0 1 21
1.51–2.25% 18 0 1 17
2.26–3.0% 23 0 2 21
5–50%
b 40 0 0 40
Total 121 3 10 108
aNonamer peptides in the SIVmac239 proteome were scored using the
matrix values derived from the Mamu-A1*02201 PSCL analysis. The final
score for each peptide represents the product of the corresponding matrix
values for each peptide residue–position pair. Peptides scoring amongst the
top 3.0% were selected for characterization
bA set of 40 control peptides scoring in the 5–50% range was also examined
458 Immunogenetics (2010) 62:451–464type alleles. Early studies examining peptide binding motifs
in human MHC molecules have shown that many HLA
molecules display significant overlap in peptide-binding
specificity (Sidney et al. 1996). The HLA-B7 supertype
motif describes MHC molecules that display a preference
for peptides that have hydrophobic or aromatic residues at
the C terminus and proline at position 2 (Sidney et al.
1995). Furthermore, HLA-B7 supertype molecules and
Mamu-A1*02201 share residues at key positions within
the B pocket where position 2 of the bound peptide
typically resides (data not shown). This provides a
molecular explanation to the observation that the HLA-B7
supertype ligand FPFKYAAAF bound Mamu-A1*02201
molecules with very high affinity. Based on this, we
hypothesized that the crossreactivity between these human
and macaque alleles might be relatively widespread (Dzuris
et al. 2000). To test this hypothesis, we selected three HIV-
derived epitopes restricted to HLA-B7-like molecules from
the literature (Rowland-Jones et al. 1995; Shiga et al. 1996;
Wilson et al. 1999) and tested them against Mamu-
A1*02201 (Table 4). The selected HIV-derived epitopes
displayed binding to Mamu-A1*02201 although the degree
of crossreactivity varied among the peptides. The HLA-
B*3501 restricted Pol 330 peptide-bound Mamu-A1*02201
(9.7 nM) almost as well as the HLA restricting element
(7.9 nM). While the HLA-B*0702 restricted Nef 68
peptide-bound Mamu-A1*02201 (230 nM), it was to a
much lesser degree than to the HLA restricting element
(1.0 nM). The remaining peptide, Nef 137, showed much
weaker binding to Mamu-A1*02201 (1140 nM) in com-
parison to its HLA restricting element (9.5 nM).
Conversely, we also tested 13 SIV-derived binders
(IC50≤500 nM) identified in the course of the analysis
described above, for binding to HLA-B7 supertype mole-
cules (HLA-B*0702, B*3501, B*5101, B*5301, and
B*5401). Ten of the 13 top peptide binders to Mamu-
IC50nM to purified molecules
Sequence Source HLA allele of restriction Restricting HLA Mamu-A1*02201
FPVTPQVPL Nef.68 B*0702 1.0 230
HPDIVIYQY Pol.330 B*3501 7.9 9.7
YPLTFGWCF Nef.137 B*5301 9.5 1140
Table 4 HLA-B7 supertype-
restricted HIV epitopes tested
for Mamu-A1*02201 binding
affinity
Fig. 4 SIVmac239-derived Mamu-A1*02201 binders tested against
HLA-B7 supertype alleles. The top 13 SIV-derived binders (Table 3)
for Mamu-A1*02201 were tested for crossreactivity with HLA-B7
supertype molecules (B*0702, B*3501, B*5101, B*5301, and
B*5401). Extensive crossreactivity between HLA-B7 supertype
molecules and Mamu-A1*02201 was demonstrated. HLA-B*0702
displayed the highest degree of crossreactivity with Mamu-A1*02201.
Affinities highlighted in blue possess an IC50<50 nM. Those affinities
in the 50–500 nM range are highlighted in green. Dashes indicate
binding affinity >10,000 nM
Immunogenetics (2010) 62:451–464 459A1*02201 also bound at least one molecule of the B7
superfamily with affinity better than 500 nM (Fig. 4). HLA-
B*0702 displayed the highest degree of crossreactivity,
binding eight out of 13 (62%) Mamu-A1*02201 binders.
Additionally, HLA-B*3501 is also highly crossreactive,
having bound seven of 13 (54%) Mamu-A1*02201 binders,
five of which were shared with HLA-B*0702.
Evolutionary origin of Chinese rhesus macaque HLA-B7
functional analogy
The data presented above illustrate that the Chinese origin
rhesus macaques exhibit a high degree of MHC haplotypic
diversity and that it is largely non-overlapping with rhesus
macaques of Indian origin. Functionally, the most common
Chinese allele described above is associated with an HLA-
B7 supertype specificity never, thus far, detected in Indian
macaques, despite analysis of many of the most common
alleles expressed in this animal.
To investigate the origin of HLA-B7 specificity in
Chinese-origin rhesus macaques, we built a phylogenetic
tree using representative MHC allele sequences from
humans and both Indian and Chinese rhesus macaques.
For humans, we included one HLA allele (HLA-
A*01010101, HLA-A*02010101, HLA-A*03010101,
HLA-A*24020101, HLA-B*070201, HLA-B*080101, HLA-
B*270502, HLA-B*44020101, HLA-B*580101, and HLA-
B*150101) from each of the known supertypes (A1, A2,
A3, A24, B7, B8, B27, B44, B58, and B62, respectively)
and the four additional HLA-B7 supertype alleles (HLA-
B*350101, HLA-B*510101, HLA-B*530101,a n dHLA-
B*5401) that were used in this study. For Indian rhesus
macaques, we selected 14 sequences represented among the
most common specificities, namely Mamu-A*00101,
Mamu-A*00201,M a m u - A*00301,M a m u - A*00401,
Mamu-A*00701,M a m u - A*00801,M a m u - A*01101,
Mamu-B*0010101,M a m u - B*00201,M a m u - B*00501,
Mamu-B*00701,M a m u - B*00801,M a m u - B*01201,a n d
Mamu-B*01701 (Boyson et al. 1996; Kaizu et al. 2007;
Knapp et al. 1997; Loffredo et al. 2007; Voss and Letvin
1996). Similarly, the 14 Chinese rhesus macaques sequen-
ces included in the analysis were selected from the most
frequent alleles listed in Table 2 above.
Despite functional evidence that Mamu-A1*02201 is an
analog of HLA-B7 supertype molecules, the resulting
phylogenetic tree (Fig. 5) shows that this Mamu allele
appears in the Mamu-A group, and not Mamu-B. This
suggests that HLA-B7 specificity in humans and macaques
did not arise through persistence of a common B7-like
allele. On the contrary, these data indicate that HLA-B7
supertype specificity has arisen independently in humans
and macaques, most likely as a result of convergent
evolution (Sette and Sidney 1999).
Discussion
Herein, we present the first functional characterization of a
Chinese rhesus macaque MHC class I molecule. Our study
stems from the analysis of MHC class I sequences derived
from a sample of 50 different rhesus macaques of Chinese
origin. The results highlighted an extreme degree of
polymorphism at the A and B class I loci of Chinese
rhesus macaques, possibly reflective of the vast geograph-
ical region from which they originated, which supports
large populations with limited genetic interchange. This
situation favors the generation and maintenance of inde-
pendent polymorphisms in the species. Indeed, previous
analysis of mitochondrial DNA in captive rhesus macaque
populations showed greater genetic diversity in Chinese-
origin versus Indian-origin rhesus macaques (Kanthaswamy
and Smith 2004; Satkoski et al. 2008).
Our results further indicated that the polymorphisms
found in Chinese macaques are largely non-overlapping
with the polymorphisms associated with the more thor-
oughly investigated Indian macaques. This likely reflects
the geographical distance between India and China and the
low frequency of contemporary genetic exchanges between
the two populations. These results also have practical
implications, as they suggest that the alleles associated
with specific disease resistance and susceptibility found in
Indian rhesus macaques will not be found in Chinese
rhesus, and thus, new correlations will need to be
established. Conversely, the rich polymorphisms of MHC
class I alleles in Chinese rhesus represent a valuable
opportunity for the scientific community, as it is likely that
new interesting phenotype associations will be revealed,
thus helping to further the understanding of host–pathogen
interactions. A recent study using next-generation sequenc-
ing technology indicated that the number and polymor-
phism of class I alleles expressed in these animals may
have been vastly underestimated (Wiseman et al. 2009).
Such advances in technology are revealing an unprecedent-
ed array of sequences in Chinese macaques, but this only
underscores the need to continue investigating the func-
tional implication of such polymorphism and disease
outcome correlations.
Perhaps the most striking observation resulting from our
studies is the most common MHC class I allele found in the
disparate Chinese rhesus macaque colonies we examined is
associated with HLA-B7 supertype specificity. The HLA-
B7 supertype is estimated to be the most abundant super-
type represented in the human population with an average
prevalence of 49.5% across various ethnic groups (Sette
and Sidney 1999). Our finding is significant in light of the
fact that this specificity is thus far absent from the Indian
rhesus MHC class I alleles characterized to date, which
represent a large majority of typed animals (Allen et al.
460 Immunogenetics (2010) 62:451–4641998; Dzuris et al. 2000; Hickman-Miller et al. 2005; Kaizu
et al. 2007; Knapp et al. 1997; Loffredo et al. 2007, 2009;
Mothe et al. 2002). The selective forces responsible for the
repeated appearance of HLA-B7 specificities may some-
how be absent in the Indian rhesus environment. Alterna-
tively, a catastrophic bottleneck event could have
eliminated this specificity from Indian rhesus populations.
Similar drastic events appeared to have shaped the
evolution of MHC polymorphism in the case of chimpan-
zees (de Groot et al. 2002). A remaining possibility is that a
founder effect occurred due to limited representation of
some class I alleles in the Indian rhesus macaques that were
imported prior to the 1978 ban, with the result that
subsequent generations show no evidence of expressing
an MHC class I molecule with HLA-B7 supertype binding
characteristics.
Mamu-A1*02201 shares a high degree of crossreactivity
with both the HLA-B*0702 and HLA-B*3501 alleles.
Previous studies have noted the similarity between specific
Mamu and HLA class I molecules such as Mamu-A*11 and
HLA-B*44 and the Mamu-B*08 and HLA-B*27 molecules
(Dzuris et al. 2000; Loffredo et al. 2009; Sette et al. 2005).
Evidence that functional HLA-B analogs may exist within
the Mamu class I proteome has been suggested (Hickman-
Miller et al. 2005) despite highly dissimilar primary amino
acid sequences in the binding pockets of the two species.
These findings suggest that, as the number of Mamu class I
molecules that are functionally characterized at the level of
peptide binding specificity increases, specific pairs of
HLA–Mamu class I molecules with similar specificity will
continue to be identified. Thus, the specific macaque alleles
could be used as stringent models of the corresponding
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Fig. 5 Phylogenetic tree of
HLA and Mamu MHC class I
sequences. Phylogenetic analy-
sis of 14 human, 14 Indian
rhesus, and 14 Chinese rhesus
MHC class I sequences is
shown. Neighbor-joining tree
created based on 1,068 aligned
nucleotide sites. Mamu sequen-
ces derived from Indian animals
are prepended with “In” and are
colored in orange. Sequences
from the Chinese animals in this
study are prepended with “Ch”
and colored in blue. Mamu-
A1*02201 is colored in yellow.
The Mamu allele demonstrating
HLA-B7-like specificity appears
in the Mamu-A group and not
Mamu-B, indicating this motif
specificity between humans and
macaques likely did not arise
through persistence of a com-
mon allele
Immunogenetics (2010) 62:451–464 461human HLA class I molecule, or conversely, observations
relating to the specific Mamu molecules might inform
analysis targeting specific human HLA class I variants.
Finally, our investigations reveal a set of 11 alleles,
which, taken together, are found in multiple independent
macaque colonies. We extrapolate from our and previous
data that about 68% of animals in a given macaque colony
will be positive for at least one of these alleles. It should be
straightforward to establish PCR-SSP assays for these
alleles and validate them as a genotyping tool for the
scientific community. Likewise, we anticipate that peptide
binding motifs can be defined for the most common
Chinese rhesus MHC class I molecules following the
approach utilized herein to characterize in detail the
specificity of Mamu-A1*02201. The availability of detailed
motifs will, in turn, allow prediction of epitopes restricted
by the various common Chinese rhesus MHC class I
molecules, as has been done for rhesus of Indian origin
(Peters et al. 2005). These algorithms will be regularly
updated in the Immune Epitope Database Analysis Re-
source website (http://tools.iedb.org; Zhang et al. 2008),
which is freely available to the scientific community.
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